Date:5/18/2010

ogy such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions. In particular, the quotations from management in this press release contain forward-looking statements. These forward looking statements are based upon management's current views and expectations with respect to future events and are not a guarantee of future performance. Furthermore, these statements are, by their nature, subject to a number of risks and uncertainties that could cause actual performance and results to differ materially from those discussed in the forward-looking statements as a result of a number of factors. Further information regarding these and other risks is included in Simcere's filings with the U.S. Securities and Exchange Commission at www.sec.gov. Simcere does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Conference Call

Simcere Pharmaceutical Group will host a conference call to discuss the Company's results for the first quarter of 2010 on Tuesday, May 18, at 8:00 a.m. Eastern Time (Tuesday, May 18 at 8:00 p.m. Beijing/Hong Kong time). The management team will be on the call to discuss the results for first quarter of 2009 and to answer questions.

    To access the conference call, please dial:

     United States toll-free dial-in number:             +1 866 730 5769
     United States toll/International dial-in number:    +1 857 350 1593
   
'/>"/>
SOURCE  Simcere Pharmaceutical Group
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 
Related medicine technology :

1. Simceres Diosmectite API Passes EU-GMP Inspection
2. Simcere Pharmaceutical Group Successfully Completes Endostar Phase IV Clinical Study
3. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Tuesday, March 16, 2010
4. Simcere Receives SFDA Approval to Manufacture and Sell Zanamivir in China
5. Simcere Pharmaceutical Group Provides Update on Jiangsu Yanshen
6. Simcere Pharmaceutical Group Announces Jiangsu Yanshens Voluntary Suspension of Production
7. Simcere Pharmaceutical Group to Acquire Additional Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd.
8. Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals
9. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
10. Epix Pharmaceuticals, Inc. Announces Additional Information Concerning the May 28, 2010 Auction Sale of EP-3600 MRI Imaging Agent
11. Isis Pharmaceuticals to Discuss Its Cancer Franchise in a Conference Call on Wednesday, May 19